Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

This study is ongoing, but not recruiting participants.
Celgene Corporation
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center Identifier:
First received: August 5, 2011
Last updated: November 22, 2016
Last verified: November 2016

August 5, 2011
November 22, 2016
February 2012
February 2017   (Final data collection date for primary outcome measure)
Clinical Response Rate Following Induction Chemotherapy [ Time Frame: 9 weeks ]
Evaluation of target lesions via imaging with CT or MRI scans at 2-3 weeks post induction chemotherapy.
Same as current
Complete list of historical versions of study NCT01412229 on Archive Site
  • Rate of Complete Response following Induction Chemotherapy [ Time Frame: Baseline evaluation to 3 weeks after induction chemotherapy ]
    Report the rate of complete responses, defined as disappearance of all target lesions, following induction chemotherapy.
  • Progression Free Survival and Overall Survival [ Time Frame: 5 years ]
    Imaging of target lesions via CT or MRI scan post induction chemotherapy and chemoradiotherapy every 3 months for at least one year, and every 6 months for at least one year following completion of definitive chemoradiotherapy with or without surgery
  • Toxicity evaluation [ Time Frame: 2 years ]
    Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.
  • Quality of Life [ Time Frame: 2 years ]
    ECOG Performance status and FACT-HN will be completed at screening, 3 weeks post induction chemotherapy, 6 weeks post concomitant chemoradiotherapy, every 3 months in the first year, and every 6 months in the second year.
Same as current
Not Provided
Not Provided
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
A Phase II Study of Carboplatin, Nab-paclitaxel and Cetuximab for Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy. Patients must have ECOG performance status of 0-1 with good organ function and will be treated with six weekly cycles of carboplatin, nab-paclitaxel and cetuximab prior to scheduled concomitant chemoradiation. The study is designed to evaluate whether this induction regimen can result in an improved response rate (complete response (CR) + partial response (PR)) with less toxicity than the current standard induction TPF regimen which includes docetaxel, cisplatin and 5-fluorouracil (5FU).
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Head and Neck Cancer
  • Drug: Cetuximab
    Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
    Other Name: Erbitux
  • Drug: Nab-paclitaxel
    Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
    Other Name: Abraxane
  • Drug: Carboplatin
    Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
    Other Name: Paraplatin
Experimental: Treatment
  • Drug: Cetuximab
  • Drug: Nab-paclitaxel
  • Drug: Carboplatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
February 2018
February 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed SCCHN or poorly differentiated or undifferentiated cancer of the head and neck.
  • Measurable disease.
  • All primary sites are eligible excluding nasopharyngeal.
  • Surgically unresectable and/or N2b or greater nodal disease; NOTE: surgical unresectability will be defined as the combination of the treating surgeon's judgment of unresectability plus one of the following objective criteria:

    • Encasement of tumor or nodes to the carotid artery or ¾ encasement of the carotid artery.
    • Involvement of prevertebral musculature
    • Invasion of the bone of the skull base
    • Need for glossectomy or extensive glossal resection where functional outcome is considered unacceptable to surgeon or patient
    • Involvement of the cervical spine
    • Severe, unacceptable functional deficit that would result from any proposed definitive surgical resection.
  • ECOG performance status 0-1
  • Prior therapy:

    • Chemotherapy: No prior chemotherapy for the treatment of SCCHN.
    • Platinum chemotherapy: No previous history of carboplatin or cisplatin therapy.
    • Nab-paclitaxel: No previous treatment with nab-paclitaxel or another taxane.
    • Cetuximab: No previous treatment with cetuximab Or another EGFR inhibitor.
    • Radiation therapy: No prior radiation to the head and neck region.
  • Age > or = 18 years. Men and women are eligible for participation.
  • Must have acceptable organ and marrow function as defined below. Laboratory tests should be completed within 14 days prior to registration:

    • ANC > or = 1,500/mm3
    • Platelets > or = 100,000/mm3
    • HgB > 9g/dL
    • Total bilirubin < or = 1.5mg/dL
    • Albumin > 2.5 g/dL
    • AST(SGOT)/ALT(SGPT) < or = 2.5X institutional upper limit of normal, alkaline phosphatase < 2.5 x upper limit of normal, GFR > 30 mL/min (by standard Cockcroft and Gault formula or measured via 24 hour urine collection)
  • No pre-existing neuropathy greater than grade I
  • Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to day 1 of study treatment.
  • Women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and for three months after completing treatment. Adequate contraception is defined as any medically recommended method (or combination of methods) as per standard of care.
  • Patients must have the ability to understand and the willingness to sign a written informed consent document.
  • Patients must have a negative result for preformed IgE antibodies to galactose-alpha-1,3,-galactose.

Exclusion Criteria:

  • Prior treatment with any of the study medications.
  • Prior radiation to any of the field required to treat the tumor.
  • Any metastatic disease.
  • The patient may have had a prior malignancy but must be disease-free for three years prior to study entry. A history of superficial non-melanoma skin cancer or in situ carcinoma of the cervix less than three years will be allowed.
  • Pregnant or lactating female
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics, or psychiatric illness/social situations that would limit compliance with study requirements. Cardiac disease such as symptomatic congestive heart failure, unstable angina pectoris, or myocardial infarction will result in exclusion only if active within the past six months. Cardiac dysrhythmia will only result in exclusion if active and symptomatic (for example, rate-controlled atrial fibrillation will not result in exclusion).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
LCCC 1103
Not Provided
Not Provided
Not Provided
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Celgene Corporation
Principal Investigator: Jared Weiss, MD University of North Carolina, Chapel Hill
UNC Lineberger Comprehensive Cancer Center
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP